Latest Publishing News

Clinuvel Pharmaceuticals targets year-end for topline results from its pivotal vitiligo trial of SCENESSE® combined with narrowband UVB, aiming to expand the drug's use beyond its current rare disease indication.

Barton Gold’s June quarter report highlights exceptional high-grade gold and silver assay results across its South Australian projects, backed by a $26 million institutional placement that strengthens its cash position and development outlook.

Proteomics International Laboratories has streamlined operations, secured a key US patent for its endometriosis test, and inked a three-year exclusive distribution deal with Healius for its Promarker diagnostics in Australia.

Meteoric Resources has significantly boosted its Caldeira Rare Earth Project with a 246% increase in Measured Resources and pilot plant recoveries surpassing pre-feasibility targets, backed by a $40 million capital raise and advancing environmental approvals.

Newmont delivered solid second quarter 2026 results, generating $2.2 billion net income and record $2.2 billion free cash flow despite production setbacks at Cadia. The gold miner remains on track to meet full-year guidance while returning $1.9 billion to shareholders through dividends and buybacks.

Latitude 66 has locked in critical exploration permits for its high-grade KSB Project in Finland, enabling an accelerated development phase including drilling and advanced studies.

Bendigo and Adelaide Bank will redeem its A$125 million subordinated floating rate notes nearly five years ahead of maturity, with APRA approval secured for the early redemption.

Vinyl Group has expanded its media footprint through key acquisitions, boosting national audience reach and setting a clear path to profitability in FY27 with AI-driven Adaptive Media strategies.

XPON Technologies delivered a positive unaudited Group EBITDA of $1.1 million for FY26, supported by strategic divestments and a focus on its AI marketing platform Wondaris. The company improved gross margins and maintained strong customer retention despite divesting non-core businesses.

Streamplay’s Winter Burrow has crossed A$5.7 million in revenue since its November 2025 launch, driven by strong PC and console sales. The game now aims to broaden its reach with a mobile release scheduled for September 2026.

Actinogen Medical’s phase 2 trial of Xanamem in major depressive disorder with cognitive impairment reveals meaningful antidepressant effects, published in the British Journal of Psychiatry. The drug was safe and well-tolerated but did not improve cognition.

ECP Emerging Growth Limited rebounded in the June quarter with a 6.1% portfolio gain and an 8.4% lift in net tangible asset value, driven by strong performances in AI-related holdings and consumer growth stocks.